Oncology Drug Advisory Committee
![]() | This article includes inline citations, but they are not properly formatted. (June 2019) |
The Oncologic Drugs Advisory Committee (ODAC) receives requests for technical and clinical evaluation of new drugs by the U.S. Food and Drug Administration (FDA). The committee, consisting of members from academic and clinical oncology biostatistics, the general public, and the pharmaceutical industry, makes non-binding recommendations to both the CDER and CBER divisions of the FDA about the advisability of approving new medications to treat cancer.
References[]
Oncologic Drugs Advisory Committee, official webpage: https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/default.htm
External links[]
FDA Advisory Committees Calendar (including ODAC): https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm
Categories:
- Food and Drug Administration
- National agencies for drug regulation
- Regulators of biotechnology products
- Pharmacy organizations in the United States
- Cancer organizations based in the United States
- Oncology stubs
- Pharmacology stubs